Expansion of the immature B lymphocyte compartment in Graves' disease. 2023

Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
Translational and Clinical Research Institute, Newcastle University, Central Parkway, Newcastle-upon-Tyne NE1 3BZ, United Kingdom.

OBJECTIVE The specific mechanisms driving autoimmunity in Graves' disease (GD) remain largely unknown. Kappa-deleting recombination excision circles (KRECs) are circular DNA molecules generated during B cell maturation in the bone marrow which provide a measure of B cell production and proliferation. We aimed to investigate the association between KRECs and B cell subpopulations, with thyroid status and clinical outcome in GD patients. METHODS Kappa-deleting recombination excision circles were measured by quantitative real-time PCR using a triple-insert plasmid control in 132 GD patients and 140 healthy controls. In addition, KRECs in GD patients on withdrawal of antithyroid drug (ATD) and 6-10 weeks later were analysed according to a clinical outcome at 1 year. Flow cytometry was performed on isolated CD19+ B cells to quantitate 7 B lymphocyte subpopulations in 65 GD patients. RESULTS Circulating KRECs were higher in GD vs. controls (P = 1.5 × 10-9) and demonstrated a positive correlation to thyroid hormones and autoantibodies (free thyroxine: P = 2.14 × 10-5, rho = .30; free triiodothyronine: P = 1.99 × 10-7, rho = .37; thyroid stimulating hormone receptor autoantibodies: P = 1.36 × 10-5, rho = .23). Higher KRECs in GD patients 6-10 weeks after ATD withdrawal were associated with relapse of hyperthyroidism at 1 year (P = .04). The KRECs were positively correlated to the total CD19+ B cell count (P = 3.2 × 10-7). CONCLUSIONS This study reports a robust association between KRECs and GD, highlighting the importance of B cells in the pathogenesis of GD and the influence of thyroid status on B cell activity. The findings indicate a potential role for KRECs as a marker of disease activity and outcome in GD.

UI MeSH Term Description Entries
D006980 Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. Hyperthyroid,Primary Hyperthyroidism,Hyperthyroidism, Primary,Hyperthyroids
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013956 Antithyroid Agents Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones. Antithyroid Agent,Antithyroid Drug,Goitrogen,Goitrogens,Thyroid Antagonists,Antithyroid Drugs,Antithyroid Effect,Antithyroid Effects,Agent, Antithyroid,Agents, Antithyroid,Antagonists, Thyroid,Drug, Antithyroid,Drugs, Antithyroid,Effect, Antithyroid,Effects, Antithyroid
D013963 Thyroid Hormones Natural hormones secreted by the THYROID GLAND, such as THYROXINE, and their synthetic analogs. Thyroid Hormone,Hormone, Thyroid,Hormones, Thyroid
D014284 Triiodothyronine A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. Liothyronine,T3 Thyroid Hormone,3,3',5-Triiodothyronine,Cytomel,Liothyronine Sodium,Thyroid Hormone, T3
D054448 Precursor Cells, B-Lymphoid Lymphocyte progenitor cells that are restricted in their differentiation potential to the B lymphocyte lineage. The pro-B cell stage of B lymphocyte development precedes the pre-B cell stage. B-Lymphoid Precursor Cell,Immature B Cell,Immature B-Cell,Immature B-Lymphocyte,Immature B-Lymphocytes,Pre-B Cell,Pre-B Lymphocyte,Pre-B Lymphocytes,Pre-B-Cell,Precursor B-Cell,Precursor B-Lymphocyte,Precursor B-Lymphocytes,Pro-B Cell,Pro-B Lymphocyte,Pro-B-Cell,Progenitor B-Cell,Progenitor B-Lymphocyte,Progenitor B-Lymphocytes,Transitional B-Cell,Transitional B-Lymphocyte,Transitional B-Lymphocytes,B-Lymphoid Precursor Cells,Immature B-Cells,Pre-B Cells,Pre-B-Cells,Precursor B-Cells,Pro-B Cells,Pro-B Lymphocytes,Pro-B-Cells,Progenitor B-Cells,Transitional B-Cells,B Cell, Immature,B Cells, Immature,B Lymphoid Precursor Cell,B Lymphoid Precursor Cells,B-Cell, Immature,B-Cell, Precursor,B-Cell, Progenitor,B-Cell, Transitional,B-Cells, Immature,B-Cells, Precursor,B-Cells, Progenitor,B-Cells, Transitional,B-Lymphocyte, Immature,B-Lymphocyte, Precursor,B-Lymphocyte, Progenitor,B-Lymphocyte, Transitional,B-Lymphocytes, Immature,B-Lymphocytes, Precursor,B-Lymphocytes, Progenitor,B-Lymphocytes, Transitional,Cell, B-Lymphoid Precursor,Cell, Immature B,Cell, Pre-B,Cell, Pro-B,Cells, B-Lymphoid Precursor,Cells, Immature B,Cells, Pre-B,Cells, Pro-B,Immature B Cells,Immature B Lymphocyte,Immature B Lymphocytes,Lymphocyte, Pre-B,Lymphocyte, Pro-B,Lymphocytes, Pre-B,Lymphocytes, Pro-B,Pre B Cell,Pre B Cells,Pre B Lymphocyte,Pre B Lymphocytes,Precursor B Cell,Precursor B Cells,Precursor B Lymphocyte,Precursor B Lymphocytes,Precursor Cell, B-Lymphoid,Precursor Cells, B Lymphoid,Pro B Cell,Pro B Cells,Pro B Lymphocyte,Pro B Lymphocytes,Progenitor B Cell,Progenitor B Cells,Progenitor B Lymphocyte,Progenitor B Lymphocytes,Transitional B Cell,Transitional B Cells,Transitional B Lymphocyte,Transitional B Lymphocytes

Related Publications

Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
January 1987, Blood cells,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
December 1987, Clinical endocrinology,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
June 2008, Ugeskrift for laeger,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
March 2014, Nature immunology,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
December 1976, Clinical and experimental immunology,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
November 1989, The Journal of clinical endocrinology and metabolism,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
August 1994, Endocrine research,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
March 2014, The American journal of the medical sciences,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
July 2001, Arthritis and rheumatism,
Laura Claire Lane, and Timothy David Cheetham, and Salman Razvi, and Kathleen Allinson, and Simon Henry Schofield Pearce
July 1987, The New England journal of medicine,
Copied contents to your clipboard!